Searched over 200M research papers
10 papers analyzed
These studies suggest ACE inhibitors work by reducing angiotensin II activity, increasing nitric oxide production, and enhancing bradykinin signaling, which collectively help treat cardiovascular, renal, and metabolic diseases.
20 papers analyzed
Angiotensin-converting enzyme (ACE) inhibitors are a class of medications widely used in the treatment of cardiovascular and renal diseases. They are particularly effective in managing hypertension, heart failure, and diabetic complications . This article explores the multifaceted mechanisms through which ACE inhibitors exert their therapeutic effects.
ACE inhibitors primarily function by blocking the conversion of angiotensin I to angiotensin II (Ang II), a potent vasoconstrictor. By reducing Ang II levels, these drugs decrease systemic vascular resistance, which helps lower blood pressure without increasing heart rate . This mechanism is crucial in treating hypertension and reducing the risk of cardiovascular events such as myocardial infarction and stroke.
Ang II also promotes cardiac and renal hypertrophy and fibrosis. By inhibiting Ang II, ACE inhibitors help prevent these pathological changes, thereby protecting the heart and kidneys from long-term damage . This is particularly beneficial in conditions like congestive heart failure and diabetic nephropathy, where organ protection is paramount .
Another significant mechanism of ACE inhibitors is the enhancement of bradykinin activity. Bradykinin is a vasodilatory and natriuretic peptide that promotes blood vessel relaxation and sodium excretion. ACE inhibitors prevent the breakdown of bradykinin, thereby increasing its levels and contributing to vasodilation and natriuresis . This dual action on Ang II and bradykinin makes ACE inhibitors highly effective in managing hypertension and heart failure .
Bradykinin also has anti-inflammatory and antioxidant properties. By increasing bradykinin levels, ACE inhibitors help reduce oxidative stress and inflammation, which are key factors in the progression of cardiovascular and renal diseases . This contributes to the overall cardioprotective and renoprotective effects of these drugs .
ACE inhibitors have been shown to improve insulin sensitivity and glucose metabolism, making them particularly beneficial for hypertensive patients with type 2 diabetes. They enhance glucose uptake in insulin-resistant skeletal muscle by increasing nitric oxide (NO) production through bradykinin B2 receptors and by reducing the inhibitory effects of Ang II on glucose transport . This dual mechanism helps improve overall metabolic control in diabetic patients.
Recent studies have identified a novel mechanism involving the inhibition of N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) hydrolysis. This action contributes to the antifibrotic effects of ACE inhibitors, reducing cardiac fibrosis and cell proliferation in conditions like hypertension-induced left ventricular hypertrophy. This expands the therapeutic potential of ACE inhibitors beyond traditional uses.
There is growing interest in natural ACE inhibitors derived from plants, which offer similar benefits with potentially fewer side effects. Various plant species and bioactive compounds have been identified with significant ACE-inhibitory activity, providing a promising alternative for managing hypertension and diabetes-related complications.
ACE inhibitors are versatile medications that offer multiple therapeutic benefits through their actions on Ang II and bradykinin. They effectively manage hypertension, heart failure, and diabetic complications by reducing vasoconstriction, promoting vasodilation, and improving metabolic control. Emerging research continues to uncover new mechanisms and potential uses, further solidifying their role in modern medicine.
Most relevant research papers on this topic